These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

681 related items for PubMed ID: 15519006

  • 41. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
    Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Palmer G, Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group.
    Am J Cardiol; 2004 Sep 15; 94(6):720-4. PubMed ID: 15374773
    [Abstract] [Full Text] [Related]

  • 42. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G, Di Garbo V, Abruzzese G, Campisi D, De Simone R, Raneli G, Licata G.
    Int Angiol; 2006 Mar 15; 25(1):26-34. PubMed ID: 16520721
    [Abstract] [Full Text] [Related]

  • 43. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
    Hirsch M, O'donnell J, Olsson A.
    Int J Cardiol; 2005 Oct 10; 104(3):251-6. PubMed ID: 16186052
    [Abstract] [Full Text] [Related]

  • 44. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.
    Metabolism; 2007 Nov 10; 56(11):1534-41. PubMed ID: 17950105
    [Abstract] [Full Text] [Related]

  • 45. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study.
    Schrott HG, Knapp H, Davila M, Shurzinske L, Black D.
    Am Heart J; 2000 Aug 10; 140(2):249-52. PubMed ID: 10925339
    [Abstract] [Full Text] [Related]

  • 46. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 10; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 47. Achieving cholesterol target in a managed care organization (ACTION) trial.
    Straka RJ, Taheri R, Cooper SL, Smith JC.
    Pharmacotherapy; 2005 Mar 10; 25(3):360-71. PubMed ID: 15843283
    [Abstract] [Full Text] [Related]

  • 48. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group.
    Diabetes Obes Metab; 2005 Jul 10; 7(4):430-8. PubMed ID: 15955130
    [Abstract] [Full Text] [Related]

  • 49. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E.
    J Am Coll Cardiol; 2009 Dec 15; 54(25):2358-62. PubMed ID: 20082923
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study.
    Leibovitz E, Harats D, Gavish D.
    Isr Med Assoc J; 2002 Jun 15; 4(6):407-10. PubMed ID: 12073409
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.
    McCrindle BW, Ose L, Marais AD.
    J Pediatr; 2003 Jul 15; 143(1):74-80. PubMed ID: 12915827
    [Abstract] [Full Text] [Related]

  • 54. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
    McKenney J, Ballantyne CM, Feldman TA, Brady WE, Shah A, Davies MJ, Palmisano J, Mitchel YB.
    MedGenMed; 2005 Jul 14; 7(3):3. PubMed ID: 16369229
    [Abstract] [Full Text] [Related]

  • 55. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ, Chen ML, Wang S, Dong J, Zeng P, Hou LW.
    Chin Med J (Engl); 2004 Feb 14; 117(2):163-7. PubMed ID: 14975195
    [Abstract] [Full Text] [Related]

  • 56. Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients.
    Kanbay M, Yildirir A, Bozbas H, Ulus T, Bilgi M, Muderrisoglu H, Akcay A, Ozdemir FN.
    Ren Fail; 2005 Feb 14; 27(3):297-303. PubMed ID: 15957546
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM.
    Am J Cardiol; 2005 Aug 22; 96(4A):60E-66E. PubMed ID: 16098846
    [Abstract] [Full Text] [Related]

  • 60. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T, Laloi-Michelin M, Virally M, Peynet J, Giraudeaux V, Kévorkian JP, Guillausseau PJ.
    Eur J Intern Med; 2009 Mar 22; 20(2):197-200. PubMed ID: 19327612
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.